Information  X 
Enter a valid email address

Sensyne Health PLC (SENS)

  Print      Mail a friend

Thursday 10 September, 2020

Sensyne Health PLC

Sensyne Health appoints Chief Operating Officer

RNS Number : 5419Y
Sensyne Health PLC
10 September 2020
 

Sensyne Health appoints Chief Operating Officer   

 

 

Oxford, U.K. 10 September 2020 : Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, announces that it has appointed Michael Macdonnell to its senior management team as Chief Operating Officer (COO) reporting to the CEO Lord Drayson. Michael will join Sensyne with effect from 28 September 2020.

Michael is currently Director of Global Deployment at Google Health, which he joined from Google DeepMind. Prior to joining Google, Michael was National Director of System Transformation and Director of Strategy at NHS England where he oversaw the delivery of key strategic initiatives including the NHS Five Year Forward View and the development of integrated care systems.

Previously, Michael has held roles at Accenture, the Centre for Health Policy, Imperial College London and as an advisor at the Prime Minister's Delivery Unit.

Michael remains an honorary fellow at the Institute of Global Health Innovation, Imperial College London, and is a Policy Fellow at the Centre for Science and Policy, University of Cambridge. 

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"Michael brings deep healthcare expertise and a strong track-record of driving healthcare improvements through the application of advanced technology. His experience of applying artificial intelligence to real-world research and clinical practice, in collaboration with both NHS and US-based healthcare providers, will be crucial in helping Sensyne to grow to its next stage of development. Importantly, he also strongly values social purpose, which matches Sensyne's unique business model and ethical approach to the use of clinical AI."

Michael Macdonnell, said:

"Sensyne is an exceptional opportunity: a company that combines social impact with the capabilities to effect real change in how healthcare is delivered. Data insights and digital therapeutics could bring about an era of proactive or anticipatory care and disrupt a model of medicine too often based on the average patient. By working and sharing value with our healthcare partners, we can build a game-changing portfolio of technologies that will improve care for patients in the NHS and around the world."

 

-ENDS-

 

 

For more information please contact:

Sensyne Health ( www.sensynehealth.com )

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng FMedSci, Chief Executive Officer


Michael Norris, Interim Chief Financial Officer


Consilium Strategic Communications

+44 (0) 7780 600290

Mary-Jane Elliott


Sukaina Virji


Melissa Gardiner


CSC [email protected]


 

About Sensyne Health  

 

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRAVKLFBBKLFBBX

a d v e r t i s e m e n t